



Humedix

Investor Relations

1Q 2022

본 문서는 대한 회계기준을 적용하여 작성된 미래 성과에 대한 전망 관련 투자자료로써, 투자목적용 자료입니다.

Disclaimer

All information in this book including business performance and financial report is written by Korean-International Financial Reporting Standards(K-IFRS) .

This book includes a "forecast" about future. It is not about the past, but the future business plan including expected management status and financial performance, and sometimes there can be word such as 'anticipation', 'forecast', 'plan', 'expectation', and '(E)'.

A "forecast" can mean uncertain factors which can affect the company either positively or vice versa, and those can include:

- Domestic or international financial market trends including fluctuation of foreign exchange rate or interest rate.
- Company's very important strategic decision such as M&A
- Unexpected business environment change in the main industry
- Other internal and external change that can affect the company's management and finance.

Because of those uncertain risks, company's actual business performance can be different from the "forecast" in this booklet. Also the information we provide is written as of the day we deliver the presentation, so it can be changed due to unexpected external status of industry or internal company's revision of strategies without any prior notice in the future.



본 문서는 대한 회계기준을 적용하여 작성된 미래 성과에 대한 전망 관련 투자자료로써, 투자목적용 자료입니다.


Key Highlights

Performance & Finance	✓ 1Q 2021 Revenue 26.9(YoY +24%), OP 4.3(YoY +63%) (Unit; Billion KRW)
Aesthetic	Total Aesthetic Solution : Filler(Elravie) + Medical Device(Derma Shine) + Botulinum toxin(LIZTOX) Domestic sales network Expansion
NEW Business	Eye-drop Line New Factory(Heparin Sodium)
Main Business	New Elravie filler, LIZTOX 50/200 Unit, PN Joint injection CMO Business(PFS, Amp, Vial) Ultra-high low molecule HA

Contents

- 01 Company Overview
- 02 Vision
- 03 Business performance
- 04 Business field
- 05 R&D & Business Strategy


“Total Healthcare Group”
Includes Pharma, Medical Device, Health Functional Food and Cosmetic business



Kim, Jin Hwan	Yoon, Sung Tae	Leem, Mun Jeong	Koh, joong shik	Park, Seung Bae	Hong, Kyung Ho
President CEO	Chairman Executive Director	Executive Director	Director Outside Director	Director Outside Director	Director Outside Director
Head of Sales Marketing Division Huons BA Education At Chung-Ang Univ.	Chairman of Huons Group IBM KOREA MS Project Mgt. At Hanyang Univ.	Strategic Development Headquarters Dongwha Pharma Ph.D in pharmacy At Sungkyunkwan Univ.	Director of Accounting Supervision, Financial Supervisory Service Outside Director, Hyundai Motor Securities College of Law, LL.B. At Korea Univ.	Bae, Kim & Lee LLC Senior Advisor Korea Exchange (Stock Exchange) College of Law, LL.D. At Yonsei Univ.	Associate, Yoon & Yang LLC Prosecutor, Suwon District Public Prosecutor's Office College of Law, LL.B. At Korea Univ.

Bio-specialized Company

- Securing growth engines through Strategic Partnerships
- Concluded domestic and foreign exclusive sales rights and research agreements with companies



7


“Sales growth & Profit improvement”

[Separate]

(Unit : Billion KRW)

■ Operating income
■ Profit

(Unit : Billion KRW)




	2019	2020	2021	1Q 2021	1Q 2022
Revenue	69.0	80.4	93.7	21.7	26.9
Operating income	9.4	12.2	12.2	2.6	4.3
Profit	8.8	13.3	9.0	2.5	11.4

8

[Business Structure]

Filler, LIZTOX	<ul style="list-style-type: none"> High purity HA ingredient Superior viscosity/elasticity/durability Registered in NMPA (Mar. '15) Export manufacturing techniques to Sesderma in Spain(Nov.'18) Product package strategy(Filler+LIZTOX) LIZTOX 50/200 Unit(1Q '22)
Arthritis	<ul style="list-style-type: none"> Exported the technique of 1 shot arthritis medication to China Humiaju®: Approved as an once injection type <ul style="list-style-type: none"> Strengthen exercise capacity, Less pain "Humia", Acquired European CE certification(May. '21) PN Joint injection(2023)
Pharma, CDMO	<ul style="list-style-type: none"> Approved PDRN injection 'RevitaleX' in Apr. 2018, MFDS. <ul style="list-style-type: none"> Entered into regenerative medicine market Ethical drugs (anemia, internal secretion, and etc.) Eye-drop Line(3Q '20)
API	<ul style="list-style-type: none"> Polymer/Low Molecule HA Registration(2008) Ultra-high low molecule HA Registration(Sep. '21) <ul style="list-style-type: none"> Supplied as a raw material for fillers, arthritis, eye drops, and cosmetics PDRN Registration(2018) <ul style="list-style-type: none"> Supply of raw materials for regenerative medicine and cosmetics
Cosmetics, Others	<ul style="list-style-type: none"> "Derma Elravie" Brand marketing Functional cosmetics : wrinkle care, whitening, and etc. Medical Device : Derma Shine Series, DermaAkne

[Business Area]



Filler

Osteoarthritis treatment

Product : Elravie Premier, Revolline

Product : Hihyalonce, High Hyal Plus, High Hyal

Elravie Filler + Medical Device + LIZTOX
Various product lines based on high purity HA
Domestic sales network Expansion
<ul style="list-style-type: none"> Application of advanced HI method (High molecular Ideal Reticulated Matrix)→ High viscosity, Elasticity, Safety Good volume sense compared to competing products, also excellent durability and resistance to enzymes 'Elravie Deep Line-L' NMPA registration (Dec. 2019) Four kinds of Elravie obtained European CE Certification(Dec. 2015) Contract with Sesderma of Spain to transfer filler technology (Nov. 2018) Revolline Grande filler(Apr. 2020) Export registered country : China, Indonesia, Singapore, Japan, Iran, Iraq, Kazakhstan, Ukraine, Uzbekistan, Slovakia, etc. Revolline HARA-L(Feb. 2021) PN Meso Filler : Clinical trial approval(1Q '22)
Main product line
<p><Light-L> <Deep Line-L> <Ultra Volume-L> <Ultra Volume-2mL> <Revolline HARA-L></p>

Improved usability; single-injection
Technology export and strategic alliance (HAIBIN, China)
"Humia", Acquired European CE certification(May. 2021)
<ul style="list-style-type: none"> 'Hihyalonce' launched(Jul. 2019) Licensed and contracted with Huons & Shinpoong Pharmaceutical(Jan. 2019) Patient synovia with increased inflammation factors is reverted to the normal joint synovia conditions The high viscosity and resulting lubricating activities of the joint improve joint movements and reduce pain. Excellent cost(from raw material to product) & absolute advantage of the quality(sterile material) Export registered country : High Hyal Plus (Iran, Bahrain, Vietnam, Kazakhstan, Belarus, Mexico, Dominica, etc.)/ High Eye(Malaysia, Nigeria, etc.) PN Joint injection(2023)
Main product line
<p><five-injection cycle : High Hyal> <three-injection cycle : High Hyal Plus> <one-injection cycle : Hihyalonce></p>

Cosmetics

CDMO

Product : Derma Elravie

Product : Vial , Ampules , Pre-filled Injection

Launched vegan cosmetics "Zero Line"

Developed high-functional cosmetics raw materials; HA , PDRN, Exosome

'Atoferon Calm Cream' release

- NMPA registration(Base, Ampoule, Maskpack) (Nov. 2019)
- Honey bush : Specified individual approved raw materials, Wrinkle-improving raw material
- Duty Free Shop, Home Shopping, Road Shop, Visit Sales, H&B Store
- China, United States, East O2O Biz
- moisturizing cream containing immunomodulatory substance 'Alloferon'

Main product line



< ZERO LINE> < Mask > <PDRN Ample> <Base>

Fully equipped with the latest pre-filled syringe filling facility

New growth momentum secured through operation of the second plant

Capacity : 4 times, 200 billion won production CAPA

- Introduce new disposable eye drops facility (Installation completed July. 20)
- The latest pre-filled syringe production facilities and sufficient production capacity
- Domestic HA refining business revitalized due to Japanese production suspension
- Shortening consignment production period by specializing in hyaluronic acid
- Using auxiliary materials such as syringes optimized by various evaluations


Main product line



<Revitalex prefilled> <Lincomycin> <Dexamethasone> <Eripton prefilled>

- Introduced eye drop Machine Equipment from a German Rommelag(2Q 2020)
- Securing annual production capacity of 150 million eye drops
- Expansion to the finished product business as well as the raw material business for eye drops
- Eye drops market size : Domestic (300 billion won), Overseas (5 trillion won)
- Increasing demand due to online classes and increased smartphone use

Rommelag Blow Fill Seal







Health Care Technology & Application Leader




Sort	Code	Indication	Status					
			Discovery	Preclinical	Phase I	Phase II	Phase III	Registration
Pharma	HMC2-010	osteoarthritis	[Progress bar]					
	HMC2-073	obesity treatment	[Progress bar]					
	HMC3-039	tissue penetration	[Progress bar]					
	HMC3-078	double chin improvement	[Progress bar]					
Medical devices	HMM1-021	osteoarthritis	[Progress bar]					
	HMM1-023	facial volume restoration	[Progress bar]					
	HMM1-025	improvement of facial wrinkles	[Progress bar]					
	HMM1-026	improvement of facial wrinkles	[Progress bar]					
	HMM1-047	Neck Wrinkle	[Progress bar]					
	HMM1-050	cystitis	[Progress bar]					
	HMM1-079	chin improvement	[Progress bar]					

HA Filler Manufacturing Technology Development

<p>HDRM Method</p> <p>◆ Elravie Release</p> <ul style="list-style-type: none"> - 2nd license in Korea - Korea's first monophasic filler - European CE Certification - NMPA registration - pharmaceutical raw materials - Jang Young-sil Award - High density reticulated matrix 	<p>HI Method</p> <p>◆ Elravie Premier Release</p> <ul style="list-style-type: none"> - Low-temperature crosslinking method - Optimal crosslinking efficiency - Developed filler for volume recovery - High molecular Ideal reticulated matrix 	<p>HiVE Method</p> <p>◆ HARA Release</p> <ul style="list-style-type: none"> - biphasic technology - Minimize the use of crosslinking agents - High Viscoelasticity 	<p>I-Cross Method</p> <p>◆ Elravie New</p> <ul style="list-style-type: none"> - Collection of hyaluronic acid crosslinking technology - Maximize crosslinking efficiency - Maximize cohesion - minimal Swelling in the body - US market target - Realization of optimal physical properties for indications - Ideal Crosslink
	<p>Hi-HB Method</p> <p>◆ Monophasic + Biphasic Technology Development</p> <ul style="list-style-type: none"> - Developed Korea's first monophasic filler and biphasic filler grafting technology - Optimal crosslinking efficiency 	<p>New Linker Filler</p> <p>◆ Development of new crosslinking agent filler technology</p> 	

Technical overview

- Resolving the shortage of organs for transplantation through transformation of pigs that are genetically, anatomically and physiologically similar to humans



Business area

- Development of bio-dressing and skin graft material for heterogeneous skin
- Signed a business agreement with Humedix and Genenbio (August 2021)



Necessity

- Increased demand for organ transplants due to increase in chronic diseases
- Lack of supply and demand globally
- In the U.S., the number of people waiting for transplants has increased 6 times in the last 25 years.


Long term goal

- Xenogeneic organ development
- Research on new drugs related to organ transplantation
- Transplantation technology research
- Establishment of transplant hospital



Technical overview

- It is easily broken down in the blood, and the duration of effect of water-soluble drugs in the body is increased. Improving the convenience of taking medication



SMEB™Technology(HLB Pharmaceutical)
(Smart continuous Manufacturing system for Encapsulated Biodrug) Biodrug)


Business area

- Development of anti-obesity treatment using technology (SMEB) Long-acting obesity/diabetes injection development agreement with HLB pharmaceutical(August 2021)



Necessity

- GLP-1 Receptor agonist Global Sales Growth
- Daily Medication needs to be improved → Improving Patient Satisfaction
- Increase in R&D of global pharma companies



Long term goal

- Development of continuous hair loss injection
- Development of a treatment for persistent diabetes
- Global CMC & Clinicalization

Technical overview

- 3D Printing : Machining/laminated materials according to actual data→ Technology for rapid modeling with 3D CAD
- 3D BIO Printing : Customized facial contour implants or human cells → Printing in the desired form and culturing, making corneas, cells, and mimic organs




Necessity

- Growing demand in the field of tissue regeneration
- Application of cell therapy using autologous tissue
- world market : 16.2 billion\$(2020) → 26.1 billion\$(2022), - healthcare market : 5 billion \$(2020)

Business area

- Application of dermal papilla cell culture and transplantation technology
- Transplantation and culture of dermal papilla cell culture scaffolds



Long term goal

- Development of skin mimetics
- Application of tissue regeneration engineering by simulating tissue in the human body
- Development of fast-acting drugs



API Business Expansion

HA

- DMF approval for HA API(2008)
- Ultra-high low molecule HA Registration(2021)
- Used for fillers, Osteoarthritis treatment, eye drops, etc.
- High purity HA ingredient
- High purity HA raw material refinement sales rise

PDRN

- DMF approval for PDRN API(2018)
- As it has cell regeneration effect, it is used as a raw material in the cosmetic field
- Revitalex launched(April 2018)

Hyaluronidase

- DMF Proceeding for Hyaluronidase API(4Q 2020)
- 90-95% impurities extracted from bovine testes, 5~10% main raw material, Various side effects such as anaphylaxis occur and are widely used as injections
- The market share of high-purity hyaluronidase with less side effects is expected to increase in the future
- Domestic market size(20 billion), Global market size(2,700 billion)




1 Factory




2 Factory

- Signed business cooperation with WooriB&B for the localization of Heparin sodium(Nov. 2019)
- Heparin sodium raw material drug approved by the Ministry of Food and Drug Safety(2022)
- Heparin Sodium raw material line investment for domestic production of animal-derived raw material drugs for the first time in Korea(2Q 2020)
- Entered the bio natural raw material pharmaceutical industry
- Domestic market size(20 billion), Global market size(3,700 billion)




Heparin sodium applications



- Maximize Revenue and Profit from Expanding the Esthetic Product Line
- By establishing a package sales strategy for botulinum toxin products "LIZTOX" of Huons and "Elravie series" of Humedix
- LIZTOX 50/200 Unit(1Q '22)

Product package strategy (Filler+ Medical Device+ Botulinum toxin)



Specifications

- Product Name: LIZTOX
- API: Botulinum toxin type A
- Strain history : ATCC3502
- Efficacy: Glabella wrinkle improvement
- sales : dermatology/plastic surgery

Aesthetic Portfolio Expansion

CellExosome

- Prosthematics skin booster 'CellExosome' introduction contract(Feb. 2020)
- Strengthening Aesthetic portfolio with Filler / Toxin / Aesthetic medical equipment
- Skin regeneration and elasticity effects using MTS rollers, etc.




Varrerderm MD cream

- Introduced Varrerderm MD cream of Regencare, a specialized burn scar care company
- Contains high purity beta-glucan extracted from skirt mushrooms to moisturize / protect skin
- Expected to increase new sales with medical devices added to existing aesthetic products
- Veraderm MD cream upgraded Veraderm dual balance cream MD & lotion MD release
- Safe adhesive transparent wound dressing that can be used from infants to adults (Medical device grade 2)



Cosmetics Business Diversification of Sales Network



※ Secure diverse customer base and sales channels by expanding online / offline and overseas sales network

HA (Hyaluronic Acid)			PDRN/PN (PolyDeoxyRiboNucleotide/ Polynucleotide)
Volumizing Filler	Biphasic Filler	Urology Filler	PN Joint injection, PN Meso Filler, PN Eye drops
<ul style="list-style-type: none"> ➢ Hyaluronic Acid (HA) based/naturally derived polymers ➢ Leading the filler field through the diversification of physical properties and materials ➢ clinical study phaseIII completed(3Q 2018) ➢ Launched(1Q 2019) <p>Expectation effectiveness</p> <ul style="list-style-type: none"> ➢ Safety improvement <ul style="list-style-type: none"> - Reduced HA and crosslinker content ➢ Volumizing effect of the facial area <ul style="list-style-type: none"> - Improvement of high viscosity / high elasticity / persistence 	<ul style="list-style-type: none"> ➢ Korea's first monophasic and biphasic full-line products ➢ Application of new cross link method ➢ High viscoelastic biphasic filler ➢ Completion scheduled (4Q 2020) <p>Expectation effectiveness</p> <ul style="list-style-type: none"> ➢ Development of a high viscoelastic biphasic filler that solves the problem caused by the fluidity of HA gel particles due to the low viscosity, which is a disadvantage of existing biphasic filler 	<ul style="list-style-type: none"> ➢ Higher safety compared to existing products <ul style="list-style-type: none"> - Compared to existing products (PLA, crosslink dextran) ➢ Proven safety / efficacy through clinical trials <ul style="list-style-type: none"> - Clinical trials approved by the Ministry of Food and Drug Safety - clinical study phaseIII completed(4Q 2018) - Launched(1Q 2020) <p>Expectation effectiveness</p> <ul style="list-style-type: none"> ➢ Expansion of HA filler new market with a new indication with safety / efficacy secured by clinical trials 	<ul style="list-style-type: none"> ➢ Application of high purity purified nucleic acid derived from natural materials ➢ Extraction of high-purity nucleic acid from salmon testis self-developed ➢ PDRN raw materials : KFDA(2Q 2018) ➢ PN Joint injection : Clinical trial approval (3Q 2020) ➢ PN Meso Filler : Clinical trial approval (1Q 2022) <p>Expectation effectiveness</p> <ul style="list-style-type: none"> ➢ Shortening wound healing time ➢ Collagen generation Promotion of cell differentiation ➢ Vascular endothelial cells Induction of proliferation factor

Separate Financial Information

(KRW mil)

Classification	1Q 2022	2021
Assets		
Current assets	102,014	99,577
Non-current assets	109,089	96,289
Total assets	211,103	195,867
Liabilities		
Current liabilities	43,079	37,749
Non-current liabilities	35,311	34,290
Total liabilities	78,390	72,039
Equity		
Issued capital	4,986	4,986
Capital surplus	88,982	88,463
Retained earnings	70,343	55,414
Total equity	132,713	123,828
Total equity and liabilities	211,103	195,867

Classification	1Q 2022	2021
Revenue(Sales)	26,854	93,693
Cost of sales	15,586	58,862
Gross profit	11,268	34,831
Operating income	4,307	12,196
Profit before tax	12,276	10,062
Income tax expense	868	1,072
Net income	11,409	8,990

27

이 문서에 대한 설명은 이해관계자에게 제공된 정보가 가장 정확하고 완전한 것을 보장하지 않습니다.

Thank you